Pharmacology Flashcards
Effects of Glucocorticosteroids
Anti-inflammatory
Bind & block promoter sites of proinflammatorty genes IL-1 alpha & IL-2 beta
Decreased production of TNF alpha
Multiple cell specific effects
Proinflammatory Mediators Glucocorticosteroids Inhibits
Phospholipase A2 Cyclooxygenase 2 Nitric oxide synthetase Prostaglandins Leukotrienes Thromboxanes
Effect of Glucocorticosteroids on Leukocytes
Can’t exit circulation as readily
Entry to site of infection & tissues injury impaired
Glucocorticosteroids & Suppression of Inflammatory Response
Increased neutrophils
Decreased eosinophils
Decreased monocytes
Decrease lymphocytes
Glucocorticosteroids & Effects of Acquired Immunity
Decreased APCs
Decreased T cells
Decreased B cells
Increased Infection Risk with Glucocorticosteroids
Immediate reduction of phagocytic responses
Main infections on long term therapy: herpes zoster, staph, candida
Monitoring for Toxicity of Glucocorticosteroids
BP Serum glucose Lipid profile Eye exam Bone density
Pros of Steroids
No dose adjustment in renal impairment
Good symptom relief of pain secondary to inflammation
Short Term Symptom Management for RA
NSAIDs
Steroids
NSAIDs & RA
May alleviate the symptoms
Do not prevent irreversible joint damage
Glucocorticoids & RA
Quick symptoms relief
Avoid long term administration due to toxicities
Not a profound effect on decreasing joint destruction
DMARDs & RA
Variable response
Discontinuation rate high
Continued indefinitely unless significant toxicity
Biological & non-biological
Non-Biological DMARDs
Methotrexate Sulfasalazine Hydroxychloroquine Leflunomide D-penicillamine Gold salt Azithroprine Cyclosporine
Biological DMARDs
Etanercept (Enbrel) Adilimumab (Humira) Infliximab (Remicade) Aakinra (Kineret) Abatacept (Orencia)
2nd Line if Failure to Achieve RA Remission in 3 Months
Change DMARD
Go to combination therapy
How to decide on which drug for RA?
Disease severity
Prognostic factors
Patient preference
Methotrexate (Rheumatrex)
DMARD of choice for RA
Generally well tolerated
MOA of Methotrexate (Rheumatrex)
Stimulates adenosine release
Reduced neutrophil adhesion
Suppression of cell mediated immunity
Anti proliferative effect on synovial fibroblasts & endothelial
Inhibition of IL-1, IL-6, & IL-8
Inhibits synovial collegenase gene suppression
What do all patients on methotrexate need?
Folic acid supplemet
Contraindications of Methotrexate (Rheumatrex)
Women contemplating pregnancy
Pregnancy
Liver disease or excessive ETOH intake
GFR less than 30 mL/min
SE of Methotrexate (Rheumatrex)
Hepatotoxicity Pulmonary toxicity Myelosuppression Nephrotoxicity Fatigue Decreased ability to concentrate Alopecia Nausea Stomach upset Loos stools Soreness of the mouth Rash on the extremities Headache Fever
Toxicities of Methotrexate (Rheumatrex)
Myelosuppression
Hepatotoxicity including cirrhosis
Pulmonary toxicity
Monitoring of Methotrexate (Rheumatrex)
CBC LFTs Albumin Creatinine Pre treatment CXR
2nd Line Drug for RA
Sulfasalazine (Azulfidine)
MOA of Sulfasalazine (Azulfidine)
Inhibition of PMN cell migration
Reduced lymphocyte responses
Inhibits angiogenesis
Decreases inflammatory cytokines & IgM RF production
Contraindications of Sulfasalazine (Azulfidine)
Sulfa allergy Pregnancy category D GI or GU tract obstruction Porphyria Platelet count less than 50K LFTs > 2x ULN Hepatitis Men wanting to conceive
SE of Sulfasalazine (Azulfidine)
Nausea & diarrhea Intestinal or urinary obstruction Oral ulcers Orange-yellow pigmentation of the skin Headache Depression Neutropenia Thrombocytopenia Agranulocytosis
Toxicity of Sulfasalazine (Azulfidine)
Myelosuppression
Monitoring of Sulfasalazine (Azulfidine)
CBC monthly x3
CBC every 3 months
Effects Leflunomide (Avara)
Anti-inflammatory
Antiproliferative
Decreases progression of joint erosions & joint space narrowing
MOA of Leflunomide (Avara)
Competitive inhibitor of dihydrofolate reductase
Decreases production of pyrimidine
Inhibits pyrimidine synthesis
Contraindications to Leflunomide (Avara)
Pregnancy
Preexisting liver disease
Alcoholism
SE of Leflunomide (Avara)
Diarrhea Rash Reversible alopecia Hepatotoxicity Weight loss HTN Bone marrow suppression
Leflunomide (Avara) Toxicities
Hepatotoxicity
Bone marrow suppression
Monitoring of Leflunomide (Avara)
Monthly x 6 then every 2 months
CBC
Liver enzymes
Creatinine
Interactions with Leflunomide (Avara)
Weak inhibitor of CYP2C9
Increase warfarin levels
Rifampin may increase levels of leflunomide
Bile acid sequesterants decrease effectiveness of leflunomide
Hydroxychloroquine (Plaquenil) & RA
Antimalarial
Does not limit progression of RA
Use of Hydroxychloroquine (Plaquenil)
Mild RA with no evidence of joint destruction & no inflammatory markers or autoimmune markers
Add-on to methotrexate
MOA of Hydroxychloroquine (Plaquenil)
Interferes with normal antigen processing
Inhibits lysosomal enzymes & IL-1 release
Inhibition of PMNs & lymphocyte responses